MURALI CHINTAGUMPALA to Neuroectodermal Tumors, Primitive
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Neuroectodermal Tumors, Primitive.
Connection Strength
0.889
-
A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 2009 Feb; 11(1):33-40.
Score: 0.292
-
Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. Acta Neuropathol. 2022 10; 144(4):733-746.
Score: 0.192
-
A Prospective Evaluation of Fatigue in Pediatric Brain Tumor Patients Treated With Radiation Therapy. J Pediatr Hematol Oncol Nurs. 2022 Nov-Dec; 39(6):358-365.
Score: 0.189
-
A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children. Neuro Oncol. 2014 Jun; 16(6):787-99.
Score: 0.106
-
White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004 Nov 15; 22(22):4551-60.
Score: 0.056
-
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004 Aug 15; 22(16):3357-65.
Score: 0.055